Mobile

PM1116197 is a Clinical Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo 1. ...

Mise à jour : Il y a 4 ans
Référence : U1111-1150-5007

PM1116197 is a Clinical Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo 1. Losmapimod kezelés a p38 kináz, mint terápiás célpont gátlására és az akut koronária-betegséget követő kimenetel módosítására (LATITUDE)-TIMI 60 2. Egy új készítmény vizsgálata szívrohamon átesett betegek kezelésére

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate the efficacy of oral losmapimod 7.5 mg BID compared to placebo when added to standard of care in subjects with ACS on the time to first occurrence of adjudicated MACE (defined as CV death, MI, or severe recurrent ischemia [SRI-UR]) through 12 weeks of therapy.

Critère d'inclusion

  • Subjects with ACS on the time to first occurrence of adjudicated MACE (defined as CV death, MI, or severe recurrent ischemia [SRI-UR])

Liens